No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection and requiring oxygen: results of a study using routinely collected data to emulate a target trial

From OmniJournal
Revision as of 17:07, 22 July 2020 by Jtodaro2 (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Publication
Title
Authors
  • Matthieu Mahevas
  • Viet-Thi Tran
  • Mathilde Roumier
  • ...
  • Nathalie Costedoat
Journal medRxiv preprint
Date April 14, 2020

Non-randomized trial of 181 COVID-19 patients hospitalized for hypoxic pneumonia treated with hydroxychloroquine or standard therapy with primary endpoint of transfer to ICU. Of the patients treated with hydroxychloroquine, 20% also received azithromycin. There was no difference between treatment groups in transfer to ICU or death 7 days after hospital admission.

Based on C-reactive protein levels, most patients were already in a cytokine storm by the time treatment was initiated, which supported the theory that hydroxychloroquine is unlikely to be effective once patients are in a cytokine storm.

Major Issues

No major issues identified at this time.

Minor Issues

No minor issues identified at this time.

Impact

This study supported evidence that hydroxychloroquine has minimum to non-existent effects in late stage disease where patients are in cytokine storm.

Article Revisions

None at this time.

References